Verastem, Inc. (VSTM) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $7.43. The rating moved from Oversold to Overbought on August 18, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$7.43
• Last changeMoved from Oversold to Overbought on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Verastem, Inc. is a small, development‑stage oncology company with upside linked to clinical and partnership catalysts but constrained by limited liquidity and likely near‑term financing needs. The company's valuation is highly event‑driven: positive clinical or licensing news could produce sharp gains, while trial setbacks, regulatory delays, or dilution would cause outsized downside. Given the current market tone favoring growth names, short‑term sentiment may provide support, but fundamental exposure remains tied to milestone delivery and cash management.

Key factors

• Early‑stage oncology pipeline with programs that could drive upside if clinical milestones are met
• Small market capitalization and low liquidity typical of development‑stage biotech, which amplifies volatility
• Limited or intermittent revenue; financial health depends on cash runway, partnerships, and potential financing
• Potential for near‑term clinical readouts or regulatory events to act as catalysts
• Sector dynamics: investor rotation into growth/biotech can support sentiment in risk‑on environments
• Opportunity for business development or licensing deals to de‑risk programs and provide non‑dilutive funding

Risks

• Clinical trial failures or missed endpoints that would materially impair valuation
• Short cash runway requiring equity raises that could cause significant dilution
• Regulatory setbacks or delays in key program timelines
• Strong competition from larger oncology developers or better‑funded entrants
• Low liquidity leading to outsized price moves on limited news or block trades
• Adverse shifts in biotech investor sentiment or wider risk‑off market moves that reduce access to capital

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.